SEC Form 4 · accession 0001209191-17-061256
Clearside Biomedical, Inc. · CLSD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clay Thorp
Director · 10% Owner
Period of report
Nov 14, 2017
Accepted (ET)
Nov 16, 2017 · 5:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001539029
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3,F4,F5 | Nov 14, 2017 | S | 15,000 | $7.02 | D | 3,821,394 | I | See Footnotes |
| Common StockF6,F7,F4,F5 | Nov 15, 2017 | S | 15,000 | $6.99 | D | 3,806,394 | I | See Footnotes |
| Common StockF8,F9,F4,F5 | Nov 16, 2017 | S | 5,000 | $6.99 | D | 3,801,394 | I | See Footnotes |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holders of the securities on June 12, 2017.
- F2Consists of (i) 441 shares sold by Hatteras NC Fund, LP ("Hatteras NC"), (ii) 5,752 shares sold by Hatteras Venture Partners III, LP ("HVP III"), (iii) 522 shares sold by Hatteras Venture Affiliates III, LP ("HVA III"), (iv) 930 shares sold by Hatteras Venture Partners IV, LP ("HVP IV") and (v) 7,355 shares sold by Hatteras Venture Partners IV SBIC, LP ("HVP IV SBIC").
- F3This transaction was executed in multiple trades at prices ranging from $6.90 to $7.36, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- F4The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of HVP IV and Hatteras NC. HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC.
- F5The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
- F6Consists of (i) 441 shares sold by Hatteras NC, (ii) 5,752 shares sold by HVP III, (iii) 522 shares sold by HVA III, (iv) 930 shares sold by HVP IV and (v) 7,355 shares sold by HVP IV SBIC.
- F7This transaction was executed in multiple trades at prices ranging from $6.84 to $7.16, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- F8Consists of (i) 147 shares sold by Hatteras NC, (ii) 1,918 shares sold by HVP III, (iii) 174 shares sold by HVA III, (iv) 310 shares sold by HVP IV and (v) 2,451 shares sold by HVP IV SBIC.
- F9This transaction was executed in multiple trades at prices ranging from $6.88 to $7.10, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.